Clinical Trials Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS One. 2013 Aug 5;8(8):e71239. doi: 10.1371/journal.pone.0071239. Print 2013.
To determine whether common DNA sequence variants within groups of genes encoding elements of stress-activated mitogen-activated protein kinase (MAPK) signaling pathways are, in aggregate, associated with advanced AMD (AAMD).
We used meta-regression and exact testing methods to identify AAMD-associated SNPs in 1177 people with AAMD and 1024 AMD-free elderly peers from 3 large-scale genotyping projects on the molecular genetics of AMD. SNPs spanning independent AAMD-associated genomic intervals were examined with a multi-locus-testing method (INRICH) for enrichment within five sets of genes encoding constituents of stress-activated MAPK signaling cascades.
Four-of-five pathway gene sets showed enrichment with AAMD-associated SNPs; findings persisted after adjustment for multiple testing in two. Strongest enrichment signals (P = 0.006) existed in a c-Jun N-terminal kinase (JNK)/MAPK cascade (Science Signaling, STKE CMP_10827). In this pathway, seven independent AAMD-associated regions were resident in 6 of 25 genes examined. These included sequence variants in: 1) three MAP kinase kinase kinases (MAP3K4, MAP3K5, MAP3K9) that phosphorylate and activate the MAP kinase kinases MAP2K4 and MAP2K7 (molecules that phosphorylate threonine and tyrosine residues within the activation loop of JNK); 2) a target of MAP2K7 (JNK3A1) that activates complexes involved in transcriptional regulation of stress related genes influencing cell proliferation, apoptosis, motility, metabolism and DNA repair; and 3) NR2C2, a transcription factor activated by JNK1A1 (a drugable molecule influencing retinal cell viability in model systems). We also observed AAMD-related sequence variants resident in genes encoding PPP3CA (a drugable molecule that inactivates MAP3K5), and two genes (TGFB2, TGFBR2) encoding factors involved in MAPK sensing of growth factors/cytokines.
Linkage disequilibrium (LD)-independent genomic enrichment analysis yielded associations of AAMD with aggregates of functionally related genes encoding constituents of the JNK MAPK signaling pathway. FDA-approved drugs now exist to target constituents of stress-activated MAPK pathways and may offer reasonable approaches to preventing or treating AAMD.
确定应激激活丝裂原活化蛋白激酶(MAPK)信号通路元件编码基因群中的常见 DNA 序列变异是否总体上与晚期 AMD(AAMD)相关。
我们使用荟萃回归和确切检验方法,在 3 项大型 AMD 分子遗传学基因分型项目中,对 1177 名 AAMD 患者和 1024 名无 AMD 的老年患者,确定与 AAMD 相关的 SNP。使用多基因检测方法(INRICH),对跨越独立的 AAMD 相关基因组区间的 SNP 进行检测,观察其在 5 个应激激活 MAPK 信号级联编码成分的基因集中的富集情况。
5 个信号通路基因集中有 4 个表现出与 AAMD 相关 SNP 的富集;在 2 个基因集中,在进行多重检验调整后,结果仍然存在。在一个 c-Jun N-末端激酶(JNK)/MAPK 级联(Science Signaling,STKE CMP_10827)中存在最强的富集信号(P=0.006)。在此通路中,7 个独立的与 AAMD 相关的区域存在于 25 个检测基因中的 6 个中。这些包括:1)3 个 MAP 激酶激酶激酶(MAP3K4、MAP3K5、MAP3K9),它们磷酸化并激活 MAP 激酶激酶 MAP2K4 和 MAP2K7(磷酸化 JNK 激活环中苏氨酸和酪氨酸残基的分子);2)MAP2K7 的靶点(JNK3A1),激活参与应激相关基因转录调控的复合物,影响细胞增殖、凋亡、迁移、代谢和 DNA 修复;以及 3)NR2C2,一种被 JNK1A1 激活的转录因子(一种影响模型系统中视网膜细胞活力的可用药分子)。我们还观察到与编码 PPP3CA(一种可使 MAP3K5 失活的可用药分子)的基因以及编码参与 MAPK 感知生长因子/细胞因子的因子的 TGFB2 和 TGFBR2 基因中的 AAMD 相关序列变异。
连锁不平衡(LD)非依赖性基因组富集分析得出了 AAMD 与编码 JNK MAPK 信号通路成分的功能相关基因集合之间的关联。目前已有针对应激激活 MAPK 通路的药物靶点,这可能为预防或治疗 AAMD 提供合理的方法。